公开(公告)号：US20240226000A9

公开(公告)日：2024-07-11

申请号：US18351192

申请日：2023-07-12

Applicant: Dyve Biosciences, Inc.

Inventor： Nathan FITZSIMMONS ,  Ryan BEAL ,  Charles A. HARBERT ,  Audrene RICE ,  Brandon SAND ,  Parshva KOTHARY ,  Bruce SAND

IPC: A61K9/00 ,  A61K9/06 ,  A61K31/196 ,  A61K31/4015 ,  A61K31/4035 ,  A61K31/404 ,  A61K31/415 ,  A61K31/4178 ,  A61K31/4196 ,  A61K31/436 ,  A61K31/44 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/4725 ,  A61K31/506 ,  A61K31/517 ,  A61K31/519 ,  A61K31/522 ,  A61K31/546 ,  A61K31/573 ,  A61K31/575 ,  A61K31/65 ,  A61K31/7028 ,  A61K31/7052 ,  A61K31/7064 ,  A61K33/26 ,  A61K38/07 ,  A61K38/14 ,  A61K38/48 ,  A61K47/10 ,  A61K47/12 ,  A61K47/14 ,  A61K47/24

CPC classification number: A61K9/0014 ,  A61K9/06 ,  A61K31/196 ,  A61K31/4015 ,  A61K31/4035 ,  A61K31/404 ,  A61K31/415 ,  A61K31/4178 ,  A61K31/4196 ,  A61K31/436 ,  A61K31/44 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/4725 ,  A61K31/506 ,  A61K31/517 ,  A61K31/519 ,  A61K31/522 ,  A61K31/546 ,  A61K31/573 ,  A61K31/575 ,  A61K31/65 ,  A61K31/7028 ,  A61K31/7052 ,  A61K31/7064 ,  A61K33/26 ,  A61K38/07 ,  A61K38/14 ,  A61K38/4893 ,  A61K47/10 ,  A61K47/12 ,  A61K47/14 ,  A61K47/24 ,  C12Y304/24069

Abstract: The present disclosure relates to a formulations and methods for transdermal delivery of a medicament through the skin of a subject. In aspects, the formulation comprises a therapeutically effective amount of a medicament and a penetrant portion in which the penetrant portion comprises: a phospholipid, a fatty acid ester formed from a low molecular weight alcohol, and a long-chain fatty acids. In some embodiments, the penetrant portion further comprises one or more of a viscosity-improving agent, a penetration enhancer, and an emulsifier.

公开(公告)号：US20240207232A1

公开(公告)日：2024-06-27

申请号：US18394422

申请日：2023-12-22

Applicant: Vicore Pharma AB ,  Alex Therapeutics AB

Inventor： Johan RAUD ,  Carl-Johan DALSGAARD ,  Jessica SHULL ,  Kimmy BOLKE ,  Oliver FLEETWOOD

IPC: A61K31/4178 ,  A61B5/00 ,  A61B5/08 ,  A61B5/16 ,  A61K31/138 ,  A61K31/4418 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5513 ,  A61K31/5575 ,  A61K39/395 ,  A61P11/00 ,  A61P25/22 ,  G16H20/10 ,  G16H50/30

CPC classification number: A61K31/4178 ,  A61B5/08 ,  A61B5/165 ,  A61B5/4848 ,  A61B5/4884 ,  A61K31/138 ,  A61K31/4418 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5513 ,  A61K31/5575 ,  A61K39/3955 ,  A61P11/00 ,  A61P25/22 ,  G16H20/10 ,  G16H50/30

Abstract: Aspects of the present disclosure are directed to methods of treating a patient diagnosed with an interstitial lung disease (ILD), comprising administering a pharmaceutical drug for treating the ILD in a treatment regimen effective to treat fibrosis, inflammation, and/or vasculopathy, and in conjunction with the administration of the pharmaceutical drug, engaging in a self-directed digital therapeutic program that treats patient anxiety relating to the administration of the pharmaceutical drug, wherein the engaging in the self-directed digital therapeutic program is effective to increase adherence to the treatment regimen. Suitable pharmaceutical treatments include those that are useful in the therapy of an ILD, including pharmaceutical treatments that are in some way disease-modifying and/or capable of altering the course or the pathology of the ILD or at least slowing its progression, such as such as an antifibrotic agent, an immunomodulatory imide drug (IMID) or an angiotensin II type 2 receptor agonist (ATRAG).

公开(公告)号：US20240207230A1

公开(公告)日：2024-06-27

申请号：US18173882

申请日：2023-02-24

Applicant: Vicore Pharma AB ,  Alex Therapeutics AB

Inventor： Johan RAUD ,  Carl-Johan DALSGAARD ,  Jessica SHULL ,  Kimmy BOLKE ,  Oliver FLEETWOOD

IPC: A61K31/4178 ,  A61K45/06 ,  G16H10/60 ,  G16H20/70

CPC classification number: A61K31/4178 ,  A61K45/06 ,  G16H10/60 ,  G16H20/70

Abstract: Aspects of the present disclosure are directed to methods of treating an interstitial lung disease (ILD) in a patient, comprising administering a pharmaceutical treatment that is useful in the therapy of an ILD; and, in conjunction with the administration of the pharmaceutical treatment, engaging in a digital therapeutic program that delivers cognitive behavioural therapy for the treatment of anxiety which the patient identifies as leading to possible exacerbations of the symptoms of the ILD. Suitable pharmaceutical treatments include those that are useful in the therapy of an ILD, including pharmaceutical treatments that are in some way disease-modifying and/or capable of altering the course or the pathology of the ILD or at least slowing its progression, such as such as an antifibrotic agent, an immunomodulatory imide drug (IMID) or an angiotensin II type 2 receptor agonist (ATRAG).

公开(公告)号：US12016843B2

公开(公告)日：2024-06-25

申请号：US17689666

申请日：2022-03-08

Applicant: Stealth BioTherapeutics Inc.

Inventor： Dennis Keefe ,  Guozhu Zheng ,  Vania Broccoli

IPC: A61K31/4245 ,  A61K31/135 ,  A61K31/197 ,  A61K31/4152 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/5513 ,  A61K38/30 ,  A61P25/28

CPC classification number: A61K31/4245 ,  A61K31/135 ,  A61K31/197 ,  A61K31/4152 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/5513 ,  A61K38/30 ,  A61P25/28

Abstract: The present disclosure provides novel methods for treating or preventing amyotrophic lateral sclerosis (ALS), methods for delaying the onset of neurological symptoms associated with ALS, increasing survival in subjects afflicted with ALS, and attenuating the decline of muscle strength associated with ALS in a subject in need thereof. The present disclosure also provides methods for treating or preventing α-synucleinopathy or TDP-43 proteinopathy. The methods comprise administering to the subject an effective amount of a mitochondria-targeting peptidomimetic compound, such as (R)-2-amino-N—((S)-1-(((S)-5-amino-1-(3-benzyl-1,2,4-oxadiazol-5-yl)pentyl)amino)-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropan-2-yl)-5-guanidinopentanamide, or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, and/or solvate thereof.

公开(公告)号：US20240199577A1

公开(公告)日：2024-06-20

申请号：US18419303

申请日：2024-01-22

Applicant: Protego Biopharma, Inc.

Inventor： Richard F. Labaudiniere ,  Bradley Dean Tait

IPC: C07D401/12 ,  A61K31/4155 ,  A61K31/4178 ,  A61K31/4439 ,  C07D231/12 ,  C07D403/12

CPC classification number: C07D401/12 ,  A61K31/4155 ,  A61K31/4178 ,  A61K31/4439 ,  C07D231/12 ,  C07D403/12

Abstract: Provided herein are compounds having activity against TTR related conditions, and pharmaceutically accepted salts and solvates thereof. Also provided are methods of using the compounds for inhibiting and preventing TTR aggregation and/or amyloid formation in the peripheral nerves, kidney, cardiac tissue, eye and CNS, and of treating a subject with peripheral TTR amyloidosis.

公开(公告)号：US20240189234A1

公开(公告)日：2024-06-13

申请号：US18556513

申请日：2022-04-22

Applicant: NACAMED AS

Inventor： Werner FILTVEDT ,  Jo KLAVENESS ,  Hennie Marie JOHNSEN

IPC: A61K9/16 ,  A61K9/20 ,  A61K9/50 ,  A61K31/155 ,  A61K31/165 ,  A61K31/343 ,  A61K31/40 ,  A61K31/4166 ,  A61K31/4178 ,  A61K31/43 ,  A61K31/436 ,  A61K31/522 ,  A61K31/573 ,  A61K31/635 ,  A61K31/65 ,  A61K31/7048 ,  A61K31/7068 ,  A61K33/00 ,  A61K38/13 ,  A61K47/61

CPC classification number: A61K9/1611 ,  A61K9/1694 ,  A61K9/2054 ,  A61K9/2077 ,  A61K9/5015 ,  A61K31/155 ,  A61K31/165 ,  A61K31/343 ,  A61K31/40 ,  A61K31/4166 ,  A61K31/4178 ,  A61K31/43 ,  A61K31/436 ,  A61K31/522 ,  A61K31/573 ,  A61K31/635 ,  A61K31/65 ,  A61K31/7048 ,  A61K31/7068 ,  A61K33/00 ,  A61K38/13 ,  A61K47/61

Abstract: The invention provides a process for preparing silicon particles comprising at least one drug substance, wherein said process comprises the steps: a) preparing silicon particles via chemical vapor deposition (CVD): b) loading the silicon particles prepared in step a) with at least one drug substance.

公开(公告)号：US20240173302A1

公开(公告)日：2024-05-30

申请号：US18282105

申请日：2022-03-18

Applicant: DIMERIX BIOSCIENCE PTY LTD

Inventor： Robert Pearson Shepherd ,  Nina Webster

IPC: A61K31/422 ,  A61K31/194 ,  A61K31/4025 ,  A61K31/41 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/4245 ,  A61K31/505 ,  A61K31/506 ,  A61K31/519 ,  A61K38/12

CPC classification number: A61K31/422 ,  A61K31/194 ,  A61K31/4025 ,  A61K31/41 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/4245 ,  A61K31/505 ,  A61K31/506 ,  A61K31/519 ,  A61K38/12

Abstract: A pharmaceutical composition comprising at least one endothelin A receptor inhibitor or a pharmaceutically acceptable salt thereof and at least one chemokine receptor 2 (CCR2) inhibitor or a pharmaceutically acceptable salt thereof.

公开(公告)号：US11986464B2

公开(公告)日：2024-05-21

申请号：US17734571

申请日：2022-05-02

Applicant: University of Kentucky Research Foundation

Inventor： Lisa Cassis ,  Sean Thatcher ,  Yasir Alsiraj ,  Mark Ensor ,  Eric Blalock

IPC: A61K31/439 ,  A61K31/40 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/46 ,  A61P3/06 ,  A61P9/10

CPC classification number: A61K31/439 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/46 ,  A61P3/06 ,  A61P9/10

Abstract: Methods of treating or reducing risk of aneurysm, reducing cardiovascular risk, reducing serum cholesterol, reducing serum triglycerides, and/or reducing atherosclerotic plague in a subject involve administering to the subject an effective amount of a 5HT3R antagonist.

公开(公告)号：US20240156795A1

公开(公告)日：2024-05-16

申请号：US18550919

申请日：2022-03-17

Applicant: Lankenau Institute for Medical Research

Inventor： Melvin Reichman ,  George C. Prendergast

IPC: A61K31/4418 ,  A61K9/00 ,  A61K31/155 ,  A61K31/22 ,  A61K31/405 ,  A61K31/4178 ,  A61K33/18 ,  A61K47/14 ,  A61K47/20 ,  A61P17/00 ,  A61P31/10

CPC classification number: A61K31/4418 ,  A61K9/0014 ,  A61K31/155 ,  A61K31/22 ,  A61K31/405 ,  A61K31/4178 ,  A61K33/18 ,  A61K47/14 ,  A61K47/20 ,  A61P17/00 ,  A61P31/10

Abstract: Compositions and methods for the treatment of topical infections such as onychomycosis are disclosed.

公开(公告)号：US11980610B2

公开(公告)日：2024-05-14

申请号：US16760302

申请日：2018-10-30

Applicant: SAMYANG HOLDINGS CORPORATION

Inventor： Sang Yeob Park ,  Hye Jung Lim ,  Jae Young Lee ,  Min Hyo Seo ,  Sa Won Lee

IPC: A61K31/436 ,  A61K9/00 ,  A61K31/192 ,  A61K31/366 ,  A61K31/4025 ,  A61K31/415 ,  A61K31/4178 ,  A61K31/44 ,  A61K31/47 ,  A61K31/501 ,  A61K31/502 ,  A61K31/5025 ,  A61K31/506 ,  A61K47/32

CPC classification number: A61K31/436 ,  A61K9/0053 ,  A61K31/192 ,  A61K31/366 ,  A61K31/4025 ,  A61K31/415 ,  A61K31/4178 ,  A61K31/44 ,  A61K31/47 ,  A61K31/501 ,  A61K31/502 ,  A61K31/5025 ,  A61K31/506 ,  A61K47/32

Abstract: Disclosed are an oral solid dosage form composition comprising an active ingredient and a solubilizing carrier wherein a foaming ingredient is used to improve disintegration, dispersion or dissolution, and a preparation method therefor.